USA Rare Earth Inc. specializes in the production of magnets. The company is actively developing an integrated facility that will manage the entire lifecycle of NdFeB magnet creation, from mineral sourcing and extraction to processing and final manufacturing. Within the United States, USA Rare Earth supplies its magnet products to a diverse range of sectors, including defense, automotive, aerospace, general industrial applications, healthcare, and consumer electronics.
Mixed near-term picture — Q3 earnings miss and wider-than-expected loss drove a gap-down, partially offset by positive operational milestones (first commercial MREC shipments/sales, yttrium oxide samples) and a reiterated Jefferies Buy rating.
USAR reported a Q3 2026 loss of $0.44 per share versus consensus of $0.19, with revenue of $3.0 million and a $20 million gross loss on that revenue. Shares gapped down from $8.76 to an $8.26 open on Nov 10. The wider loss, elevated cash burn ($143.7M operating cash use in Q3), and a delayed Round Top SK-1300 report (pushed to Q3 2027) weigh on near-term sentiment.
Company Press Release (GlobeNewswire)USAR began commercial-scale MREC shipments in October and recorded first sales in November under a 15-year, 100% take-or-pay offtake with US SIIE (U.S. Government-funded SPV), priced on non-China reference prices with guaranteed floors for Nd, Pr, Dy, Tb. Non-China Dy oxide prices are 14-16x China prices and Tb 6-9x, supporting revenue quality. Validates production ramp toward ~4,000 tpa TREO by Q2 2027.
Company Press Release (GlobeNewswire)USAR delivered first yttrium oxide samples from its 24/7 continuous SX demonstration plant to a major defense/medical/specialty coatings company for testing and prototyping. Positions USAR among few non-Asia producers with yttrium separation capability, a supply-constrained heavy rare earth; supports the strategic narrative and potential future commercial qualification.
Company Press Release (GlobeNewswire)Jefferies reiterated a Buy rating and $21 price target on USAR, implying substantial upside from the ~$8.3 post-earnings level. The reiteration provides a supportive analyst counterweight to the earnings-driven selloff, though the wide gap between target and price underscores execution risk.
Investing.com